Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
33.03
USD
|
-7.76%
|
|
-11.71%
|
-5.36%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,099
|
2,952
|
-
|
-
|
Enterprise Value (EV)
1 |
4,583
|
3,976
|
3,803
|
3,619
|
P/E ratio
|
-873
x
|
-315
x
|
34
x
|
23.3
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1
x
|
0.96
x
|
0.93
x
|
0.9
x
|
EV / Revenue
|
1.47
x
|
1.29
x
|
1.2
x
|
1.11
x
|
EV / EBITDA
|
17.1
x
|
14
x
|
9.86
x
|
8.78
x
|
EV / FCF
|
36.1
x
|
41
x
|
28.3
x
|
24.9
x
|
FCF Yield
|
2.77%
|
2.44%
|
3.54%
|
4.02%
|
Price to Book
|
1.78
x
|
1.51
x
|
1.39
x
|
1.28
x
|
Nbr of stocks (in thousands)
|
88,800
|
89,374
|
-
|
-
|
Reference price
2 |
34.90
|
33.03
|
33.03
|
33.03
|
Announcement Date
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3,109
|
3,080
|
3,164
|
3,271
|
EBITDA
1 |
-
|
267.3
|
283
|
385.7
|
412
|
EBIT
1 |
-
|
170.9
|
242.1
|
350
|
381.7
|
Operating Margin
|
-
|
5.5%
|
7.86%
|
11.06%
|
11.67%
|
Earnings before Tax (EBT)
1 |
237
|
1.1
|
-21.01
|
109.6
|
168.9
|
Net income
1 |
192.9
|
-3.4
|
-15.77
|
83.11
|
127.2
|
Net margin
|
-
|
-0.11%
|
-0.51%
|
2.63%
|
3.89%
|
EPS
2 |
-
|
-0.0400
|
-0.1050
|
0.9725
|
1.415
|
Free Cash Flow
1 |
-
|
127.1
|
97
|
134.6
|
145.5
|
FCF margin
|
-
|
4.09%
|
3.15%
|
4.25%
|
4.45%
|
FCF Conversion (EBITDA)
|
-
|
47.55%
|
34.27%
|
34.89%
|
35.32%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
161.92%
|
114.37%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/15/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
793
|
776.4
|
775.4
|
754.6
|
788.3
|
767.1
|
781.7
|
775.6
|
EBITDA
1 |
72.5
|
70.5
|
67.2
|
39.68
|
59.68
|
86.41
|
98.97
|
84.18
|
EBIT
1 |
63
|
45.9
|
43.3
|
34.66
|
45.89
|
71.31
|
86.26
|
75.82
|
Operating Margin
|
7.94%
|
5.91%
|
5.58%
|
4.59%
|
5.82%
|
9.3%
|
11.04%
|
9.77%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-41
|
-37.83
|
-20.22
|
7.962
|
20.25
|
22
|
Net income
1 |
28.3
|
-13.1
|
-36
|
-28.53
|
-15.29
|
5.946
|
15.42
|
16.79
|
Net margin
|
3.57%
|
-1.69%
|
-4.64%
|
-3.78%
|
-1.94%
|
0.78%
|
1.97%
|
2.17%
|
EPS
2 |
0.3200
|
-0.1500
|
-0.4100
|
-0.3200
|
-0.1700
|
0.0650
|
0.2067
|
0.1900
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/14/23
|
11/13/23
|
3/11/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
1,483
|
1,024
|
851
|
667
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
5.55
x
|
3.618
x
|
2.207
x
|
1.618
x
|
Free Cash Flow
1 |
-
|
127
|
97
|
135
|
146
|
ROE (net income / shareholders' equity)
|
-
|
4.9%
|
4.85%
|
8.53%
|
9.42%
|
ROA (Net income/ Total Assets)
|
-
|
2.88%
|
2.05%
|
3.97%
|
4.84%
|
Assets
1 |
-
|
-118
|
-770.8
|
2,095
|
2,628
|
Book Value Per Share
2 |
-
|
19.60
|
21.90
|
23.80
|
25.80
|
Cash Flow per Share
2 |
-
|
1.970
|
1.310
|
2.160
|
2.470
|
Capex
1 |
-
|
40.3
|
81.8
|
56.7
|
72
|
Capex / Sales
|
-
|
1.3%
|
2.65%
|
1.79%
|
2.2%
|
Announcement Date
|
5/15/23
|
3/11/24
|
-
|
-
|
-
|
Last Close Price
33.03
USD Average target price
39.79
USD Spread / Average Target +20.45% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.36% | 2.95B | | +17.96% | 44.96B | | +1.17% | 42.65B | | +48.77% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|